Table 2.

Prognostic factors in univariate analysis.

Prognostic factors	3 years OS	5 years OS	p
Age (years)
<35 vs. >35	25% vs. 31%	15% vs. 12%	0.2
<50 vs. >50	34% vs. 27%	12.4% vs. 11.7%	0.3
<70 vs. >70	32.2% vs. 15.4%	12.8% vs. 3.8%	0.006
Menopausal status
Postmenopausal vs. premenopausal	25.4% vs. 35%	11.3% vs. 13%	0.25
DFI (Months)
<24 vs. >24	21.7% vs. 37%	6.8% vs. 14.9%	0.004
<60 vs. >60	26% vs. 58%	8.7% vs. 25.8%	0.008
PS
(0–1) vs. ≥1	39.3% vs. 9.3%	15.2% vs. 4.6%	<0.00001
HR
ER (+) vs. ER (−)	41.5% vs. 21.4%	19% vs. 5%	<0.00001
PR (+) vs. PR (−)	42.4% vs. 22.3%	18% vs. 6.5%	<0.00001
MTS
SM vs. MM	34% vs. 29%	16.4% vs. 10.3%	0.25
Visceral vs. non visceral	26% vs. 43.5%	8% vs. 25%	<0.00001
1 site vs. >1 site	41% vs. 21%	15% vs. 9%	<0.001
Medical treatment
CT vs. HT	21% vs. 52%	4% vs. 11.5%	<0.01
Anthracyclines vs. no anthracyclines	43% vs. 23%	21% vs. 5%	0.004
Taxanes vs. anthracycline	28% vs. 43%	–	0.03
Biphosphonates vs. no biphosphonates	49% vs. 19%	23% vs. 8%	0.0003
Local treatment in SM
SPT vs. no SPT	48% vs. 24%	21% vs. 11%	0.0003
RT vs. no RT	49% vs. 29%	25% vs. 11%	0.02

Abbreviations – DFI: disease free interval; PS: performance status; HR: hormonal receptors; ER: estrogen receptor; PR: progesterone receptor; MTS: metastasis; SM: synchronous metastasis; MM: metachronous metastasis; SPT: surgery of the primitive tumor; RT: radiotherapy; CT: chemotherapy; HT: hormonotherapy.